• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec12
H.C. Wainwright Maintains Buy Rating for Vir Biotechnology with a Price Target of $15.00
11:42
Nov9
Vir Biotechnology Reports Positive Results for Chronic Hepatitis Delta Treatment SOLSTICE Trial
23:10
Nov6
Evercore ISI analyst maintains BUY rating for Vir Biotechnology
15:22
Vir Biotechnology released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 240 K (forecast USD 1.983 M), actual EPS USD -1.1742 (forecast USD -0.845)
00:00
Vir Biotechnology released FY2025 9 Months earnings on November 5 After-Market (EST), actual revenue USD 4.486 M, actual EPS USD -2.8556
00:00
Nov5
Vir Biotechnology reports Q3 revenue below IBES estimates and wider net loss
21:06

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 240 K, Net Income -163.14 M, EPS -1.1742

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.214 M, Net Income -110.96 M, EPS -0.8014

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 3.032 M, Net Income -120.97 M, EPS -0.8799

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More